Femtech startups raised over $69M in August 🔥
Here's a quick roundup of the femtech startups that raised money last month.
If you're tracking who's writing checks into this space, our VC Funds Database tracks the funds actively investing in femtech and women's health right now, including check size, stage, and thesis, updated weekly.
Funding Rounds in Femtech for August 2026
♀️ Opal Therapeutics raised $1.25M to scale its "uterus in a dish" drug discovery platform.
→ Founded by: Dr. Morgan Stanton
→ About: Scale its patient-derived organoid samples and lab infrastructure through an NSF SBIR Phase II award, and build a "uterine atlas" combining patient tissue data with computational analysis to support drug discovery for endometriosis and uterine fibroids.
♀️ Kiara Health secured pre-seed funding for its personalized fertility platform.
→ Founded by: Milan Chavarkar and Priyanka Vaidya
→ About: Advance its AI-powered Fertility Intelligence Engine, which draws on clinical history, lifestyle, biomarkers, and lab data to build personalized fertility insights and care plans for couples before they enter treatment.
♀️ Channel Medsystems secured $30M in ongoing Series C funding to expand its non-hormonal treatment for heavy periods.
→ Led by: Nelson Whistance, President & CEO
→ About: Accelerate commercial expansion of Cerene, a non-hormonal, incision-free cryotherapy device for heavy menstrual bleeding and dysmenorrhea that can be delivered in an office setting in under three minutes.
♀️ Peripear secured £1.2M to prevent perineal tearing during childbirth.
→ Founded by: Nina van Schaick and Eviatar Natan
→ About: Advance its wearable device toward first-in-human trials in Singapore. The device automates warm compress therapy on the perineum during labor, a proven but rarely consistently delivered intervention for reducing tearing.
♀️ KOVE secured CHF1.6M to reduce preterm birth risk after fetal surgery.
→ Founded by: Yannick Devaud and Kurt Ruffieux
→ About: Move its implantable device, designed to seal the fetal membrane defect left behind after fetoscopic surgery, toward its first-in-human study.
♀️ ProFound Therapeutics secured up to $35M for preeclampsia drug discovery.
→ Led by: John Lepore, MD, CEO
→ About: Apply its ProFoundry platform and agentic AI tools to placental tissue and serum samples from women with preeclampsia and eclampsia, in search of new drug targets, protein therapeutics, and biomarkers, backed by a Gates Foundation commitment.
Other Notable Moves in Women's Health
Not every headline this month was a startup raise. Two larger moves are also worth tracking if you're watching where capital and policy are moving in women's health more broadly:
Essity agreed to a $284M acquisition of Kenvue's period care business in Brazil, picking up the Carefree, Sempre Livre, and o.b. brands in the world's fourth-largest period and intimate care market. It follows Essity's $340M acquisition of Edgewell's North American period care business earlier this year.
The NHS began rolling out self-testing HPV kits to millions of women in the UK, aiming to boost cervical screening completion with an at-home swab that removes the need for a clinical visit.
August 2026 Femtech Funding, By the Numbers
- Total disclosed funding: $69M+ across 6 startup rounds, plus an undisclosed pre-seed round for Kiara Health
- Largest round: ProFound Therapeutics' up to $35M commitment from the Gates Foundation
- Most active category: Drug discovery and therapeutics (Opal Therapeutics, ProFound Therapeutics)
- Geographic spread: Deals closed across the US, UK, and Switzerland
- Smallest disclosed round: Opal Therapeutics' $1.25M NSF award
Frequently Asked Questions About Femtech
What is femtech?
Femtech (female technology) refers to software, diagnostics, products, and services that use technology to improve women's health and wellness. This includes solutions for reproductive health, pregnancy, menopause, menstrual health, pelvic and sexual health, and general wellness tailored specifically for women.
Why is femtech growing so rapidly?
The femtech market is experiencing explosive growth due to several factors: increased awareness of women's health gaps in traditional healthcare, more women in decision-making roles at VC firms, technological advancements in AI and diagnostics, and a market opportunity estimated to reach over $60 billion by 2030. Historically, women's health has been underfunded and underserved, creating massive opportunities for innovation.
What types of investors fund femtech startups?
Femtech startups are funded by a mix of traditional venture capital firms, impact investors, corporate venture arms from healthcare and pharma companies, angel investors (often with healthcare or women's health expertise), and increasingly, female-led VC funds specifically focused on women's health innovation. You can browse many of these funds, along with their check sizes and investment theses, in our VC Funds Database.
Which femtech sectors are attracting the most investment?
In August 2026, drug discovery and therapeutics platforms stood out, with Opal Therapeutics and ProFound Therapeutics both raising capital to hunt for new drug targets using patient-derived tissue and AI. Maternal health also drew strong interest, with Peripear and KOVE both raising to prevent birth-related complications.
Is femtech only for women founders?
No. While many femtech companies are founded or co-founded by women, some successful femtech companies have male or mixed-gender founding teams, including several in this month's roundup. What matters most is a deep understanding of the problem being solved and commitment to addressing real gaps in women's healthcare.
How can I track femtech funding and trends?
Subscribe to specialized newsletters and databases like EverythingStartups that provide monthly roundups of femtech funding, follow femtech-focused VCs on LinkedIn, check our VC Funds Database for active investors in the space, and join femtech communities and networks for industry insights.
.png)
